Consensus EMEIS

Stocks

Market Closed - Euronext Paris 18:55:00 01/10/2026 +03			5-day change	1st Jan Change
10.32 ^EUR	-4.71%		-14.36%	-27.98%

09-04	Emeis Société anonyme, Q1 2026 Sales/ Trading Statement Call, May 07, 2026
08-03	Emeis: Operations confirmed as under control

c84cecd05f.qbk2El_WoIGQg2d9xfgzO0LpBjL1G-X83LdTb2IMWXc.zewFWyigkfv19wYT95FmfHGwdWqBQ9Slu5oEAzp4IwbeyndhbIzF-cPuNg~e283ee727a13cd10f22fab7b7df5b78d

08-03	Emeis: Operations confirmed as under control
07-31	Emeis: Strong semester: Moving the right way
04-28	Emeis holds firm with backing from TP Icap Midcap
04-09	Emeis: Pivot from firefighting to foundations
03-26	Limited 2026 energy impact; inflation remains in focus
03-04	AlphaValue/Baader Europe Lifts Emeis Rating as Operations Normalize; Estimates Revised on Preliminary FY25 Results	MT
03-03	Emeis: Opinion change, from Sell to Reduce
02-18	Emeis: Operational beat and deleveraging milestones tempered by cautious 2026 guidance
29/10/25	Emeis: Opinion change, from Sell to Reduce
29/10/25	Emeis: Good momentum expected to extend
30/09/25	Emeis: Oddo BHF raises its target price
24/09/25	Emeis: Integrating the latest strategic real-estate partnership
04/08/25	Emeis: AlphaValue still a selller
04/08/25	Emeis: Encouraging updates in asset disposals
04/06/25	Emeis: Opinion change, from Sell to Reduce
22/04/25	Emeis: Justifying disposal progress is key
13/02/25	Emeis: Opinion change, from Sell to Add
07/02/25	Emeis: FY24: on the right track
20/11/24	Emeis: Opinion change, from Buy to Add
13/11/24	Emeis: Positive Q3 lifted by a pricing and occupancy recovery; asset sales well on-track
04/10/24	Emeis: Farewell to profit warnings (?)
03/09/24	Emeis: Target cut by -32.9%
29/07/24	Emeis: Profit warning again (and again)
04/06/24	Orpea: Integrating the detailed FY23 figures
15/05/24	Orpea: Challenging recovery in France, adequate elsewhere

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	EMEIS					+51.12%
	CVS HEALTH CORPORATION					+35.7%
	HCA HEALTHCARE, INC.					+6.44%
	NATERA, INC.					-13.88%
	FRESENIUS SE & CO. KGAA					+24.21%
	QUEST DIAGNOSTICS INCORPORATED					+6.29%
	LABCORP HOLDINGS INC.					+11.91%
	DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY					+18.77%
	TENET HEALTHCARE CORPORATION					+11.38%
	IHH HEALTHCARE					+30.68%
	Average					+18.26%
	Weighted average by Cap.					+15.15%